Targeting GPVI as a novel antithrombotic strategy

Robert K Andrews, JF Arthur, Elizabeth Gardiner

    Research output: Contribution to journalArticlepeer-review


    While platelet activation is essential to maintain blood vessel patency and minimize loss of blood upon injury, untimely or excessive activity can lead to unwanted platelet activation and aggregation. Resultant thrombosis has the potential to block blood vessels, causing myocardial infarction or stroke. To tackle this major cause of mortality, clinical therapies that target platelet responsiveness (antiplatelet therapy) can successfully reduce cardiovascular events, especially in people at higher risk; however, all current antiplatelet therapies carry an increased probability of bleeding. This review will evaluate new and emerging targets for antithrombotics, focusing particularly on platelet glycoprotein VI, as blockade or depletion of this platelet-specific receptor conveys benefits in experimental models of thrombosis and thromboinflammation without causing major bleeding complications
    Original languageEnglish
    Pages (from-to)59-68
    JournalJournal of Blood Medicine
    Publication statusPublished - 2014


    Dive into the research topics of 'Targeting GPVI as a novel antithrombotic strategy'. Together they form a unique fingerprint.

    Cite this